NCT03023202: UWCCC Molecular Tumor Board Registry

NCT03023202
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (not the expansion/optimization phase)
Exclusions: 
https://ClinicalTrials.gov/show/NCT03023202

Comments are closed.

Up ↑